Authors
Latest:
Dr. Nebhan on the Efficacy of Checkpoint Inhibitors in Older Patients With CancerCaroline Nebhan, MD, PhD, discusses the efficacy of checkpoint inhibitors in older patients with cancer.
Latest:
Dr. Sherbenou on Selecting Treatment in Late Relapsed Multiple MyelomaDaniel Sherbenou, MD, PhD, discusses selecting between available treatment options for patients with late relapsed multiple myeloma.
Latest:
For Staudt, a Keen Eye Sparks Opportunities to Dig DeeperDriven by his twin passions for music and science, Louis M. Staudt, MD, PhD, has made a career out of reading between the notes.
Latest:
Geography Should Not Be DestinyTo really advance equity in cancer care, we must think long and hard about where we apply innovation and how we measure success.
Latest:
Dr. Gafita on Prognostic Models for Treatment With 177Lu-PSMA-617 in mCRPCAndrei Gafita, MD, discusses key takeaways from a retrospective analysis evaluating lutetium-177 PSMA-617 in patients with metastatic castration-resistant prostate cancer.
Latest:
Dr. Cohen on the Importance of Obtaining an Adequate Tissue Sample in GI MalignanciesSteven J. Cohen, MD, discusses the importance of obtaining an adequate tissue sample for molecular testing in gastrointestinal cancers.
Latest:
Dr Chiang on Managing Advanced NSCLC Without Driver MutationsAnne Chiang, MD, PhD, discusses treating patients with advanced non–small cell lung cancer without driver mutations.
Latest:
On the Horizon: Exciting Prospects in the Acute Lymphoblastic Leukemia Treatment LandscapeClosing thoughts from a panel of ALL experts on improving access to therapy and how their field may evolve in years to come.
Latest:
Dr. Blue on the Importance of Early Intervention in Relapsed/Refractory Multiple MyelomaBrandon Blue, MD, discusses the importance of early intervention in relapsed/refractory multiple myeloma.
Latest:
Dr Han on the Use of HIPEC in Ovarian CancerErnest S. Han, MD, PhD, discusses the use of hyperthermic intraperitoneal chemotherapy in ovarian cancer.
Latest:
Dr. Ramakrishnan on the Evolving Landscape of CAR T-cell Therapy in DLBCLPraveen Ramakrishnan, MD, MS, discusses the evolving landscape of CAR T-cell therapy in diffuse large B-cell lymphoma.
Latest:
Advanced Prostate Cancer: Remaining ChallengesExperts discuss challenges and unmet needs in men with advanced prostate cancer who are undergoing treatment with androgen deprivation therapy.
Latest:
Dr Xu on Changes in Systemic Therapy in RCCWenxin (Vincent) Xu, MD, on evolving systemic therapy and the utilization of biomarkers in the treatment of renal cell carcinoma.
Latest:
Adverse Events Associated With Immunotherapy in the Treatment of Endometrial CancerChristian Marth, MD, PhD, reviews the adverse effects of pembrolizumab and lenvatinib in the treatment of endometrial cancer, as well as the patient experience with these treatments.
Latest:
Dr. Redjal on Technological Advances in Neurosurgical OncologyNavid Redjal, MD, FAANS, discusses technological advances that have impacted neurosurgical oncology.
Latest:
Clinical Pearls and the Future of LEMSExperts provide clinical pearls on treating Lambert-Eaton myasthenic syndrome and small cell lung cancer and share upcoming advances and trials they look forward to.
Latest:
Dr. Dalal on Graft Failure in Pediatric Non-malignant DisordersMansi Dalal, MD, discusses findings from a study investigating graft failure risk factors in pediatric patients receiving allogeneic hematopoietic stem cell transplant for non-malignant disorders.
Latest:
Dr Mohammed on the Challenges of Diagnosing BPDCNTurab J. Mohammed, MD, discusses challenges associated with the diagnosis of blastic plasmacytoid dendritic cell neoplasm, and strategies to improve early diagnosis of this disease.
Latest:
Addressing Treatment Gaps in HER2+ MBCUnmet needs regarding the selection and sequencing of therapies for patients with HER2-positive metastatic breast cancer.
Latest:
Dr. Boyle on Approaching Biomarker Testing in Lung CancerTheresa Boyle, MD, PhD, discusses the current approach to biomarker testing in lung cancer.
Latest:
Dr Elkhanany on Biological Drivers of Progression in ER+ Metastatic Breast CancerAhmed Elkhanany, MD, discusses biological drivers of disease in patients with estrogen receptor–positive breast cancer who have disease progression shortly after initiating first-line therapy, as well as the importance of performing comprehensive genetic testing in these patients to determine subsequent treatment approaches.
Latest:
Rapid Readout: HSCT With Omidubicel Achieved Robust Immune Reconstitution and Lower Rates of Severe Infection Compared to UCB TransplantationExpert hematologist/oncologist Paul Szabolcs, MD, reviews positive data from a clinical trial comparing hematopoietic stem cell transplantation and omidubicel with standard cord blood transplantation.
Latest:
Allina Health Cancer Institute Begins First-of-its-Kind Clinical Trial to Revolutionize Cancer Treatment and DiagnosisAllina Health Cancer Institute is collaborating with St. Paul-based Astrin Biosciences for a first-of-its-kind clinical trial using artificial intelligence and a simple blood draw to revolutionize how cancer is diagnosed and treated.
Latest:
Dr. Fingrut on the Association Between Ancestry, Socioeconomic Status, and HLA-Disparate GraftsWarren Fingrut, MD, discusses the association between non-European ancestry and low socioeconomic status with the receipt of HLA-disparate grafts.
Latest:
Dr. Fernandez on the Utility of Trastuzumab Deruxtecan in HER2-Low Breast CancerAileen I. Fernandez, PhD, discusses the utility of fam-trastuzumab deruxtecan-nxki in HER2-low breast cancer.
Latest:
Dr. Pandalai on Outcomes With Adjuvant HIPEC in CRCPrakash Pandalai, MD, discusses outcomes with adjuvant hyperthermic intraperitoneal chemotherapy in patients with colorectal cancer.
Latest:
UAMS Breast Cancer Program Earns National ReaccreditationThe Breast Cancer program at the University of Arkansas for Medical Sciences Winthrop P. Rockefeller Cancer Institute has earned reaccreditation from the National Accreditation Program for Breast Centers.
Latest:
BCMA-Targeting Therapies for RRMM: Future PerspectivesConsiderations for optimizing treatment with BCMA-targeting agents for patients with relapsed/refractory multiple myeloma moving forward.
Latest:
Dr Dholaria on the Use of Liso-Cel in Relapsed/Refractory CLLBhagirathbhai Dholaria, MBBS, discusses the benefits and limitations of liso-cel for patients with relapsed/refractory chronic lymphocytic leukemia.
